Weiskirchen R - Search Results

1

Factor VII activating protease (FSAP): a novel protective factor in liver fibrosis.

Martinez-Palacian A, Kanse SM, Weiskirchen R. Martinez-Palacian A, et al. Among authors: weiskirchen r. Proteomics Clin Appl. 2014 Jun;8(5-6):438-46. doi: 10.1002/prca.201300078. Epub 2014 Mar 26. Proteomics Clin Appl. 2014. PMID: 24497464 Review.

2

Changes of the hepatic proteome in murine models for toxically induced fibrogenesis and sclerosing cholangitis.

Henkel C, Roderfeld M, Weiskirchen R, Berres ML, Hillebrandt S, Lammert F, Meyer HE, Stühler K, Graf J, Roeb E. Henkel C, et al. Among authors: weiskirchen r. Proteomics. 2006 Dec;6(24):6538-48. doi: 10.1002/pmic.200600580. Proteomics. 2006. PMID: 17109383

3

Rapid genotyping of the G534E polymorphism (Marburg I) of the gene encoding the factor VII-activating protease (FSAP) by LightCycler PCR.

Tag CG, Mengsteab S, Weiskirchen R, Kanse SM. Tag CG, et al. Among authors: weiskirchen r. Clin Biochem. 2007 Sep;40(13-14):1063-4. doi: 10.1016/j.clinbiochem.2007.05.007. Epub 2007 May 26. Clin Biochem. 2007. PMID: 17574227 No abstract available.

4

Altered factor VII activating protease expression in murine hepatic fibrosis and its influence on hepatic stellate cells.

Roderfeld M, Weiskirchen R, Atanasova S, Gressner AM, Preissner KT, Roeb E, Kanse SM. Roderfeld M, et al. Among authors: weiskirchen r. Liver Int. 2009 May;29(5):686-91. doi: 10.1111/j.1478-3231.2008.01897.x. Epub 2008 Oct 15. Liver Int. 2009. PMID: 19018983

5

The Marburg I variant (G534E) of the factor VII-activating protease determines liver fibrosis in hepatitis C infection by reduced proteolysis of platelet-derived growth factor BB.

Wasmuth HE, Tag CG, Van de Leur E, Hellerbrand C, Mueller T, Berg T, Puhl G, Neuhaus P, Samuel D, Trautwein C, Kanse SM, Weiskirchen R. Wasmuth HE, et al. Among authors: weiskirchen r. Hepatology. 2009 Mar;49(3):775-80. doi: 10.1002/hep.22707. Hepatology. 2009. PMID: 19105210

6

[Liver fibrosis - pathogenesis and novel therapeutic approaches].

Tacke F, Weiskirchen R. Tacke F, et al. Among authors: weiskirchen r. Internist (Berl). 2010 Jan;51(1):21-9. doi: 10.1007/s00108-009-2419-6. Internist (Berl). 2010. PMID: 20012930 Review. German.

7

Circulating factor VII activating protease (FSAP) is associated with clinical outcome in acute coronary syndrome.

Parahuleva MS, Hölschermann H, Zandt D, Pons-Kühnemann J, Parviz B, Weiskirchen R, Staubitz A, Tillmanns H, Erdogan A, Kanse SM. Parahuleva MS, et al. Among authors: weiskirchen r. Circ J. 2012;76(11):2653-61. doi: 10.1253/circj.cj-11-1502. Epub 2012 Jul 28. Circ J. 2012. PMID: 22850287 Clinical Trial.

8

Factor VII activating protease (FSAP) exerts anti-inflammatory and anti-fibrotic effects in liver fibrosis in mice and men.

Borkham-Kamphorst E, Zimmermann HW, Gassler N, Bissels U, Bosio A, Tacke F, Weiskirchen R, Kanse SM. Borkham-Kamphorst E, et al. Among authors: weiskirchen r. J Hepatol. 2013 Jan;58(1):104-11. doi: 10.1016/j.jhep.2012.09.007. Epub 2012 Sep 16. J Hepatol. 2013. PMID: 22989567

9

Proteomic profiling in Lipocalin 2 deficient mice under normal and inflammatory conditions.

Labbus K, Henning M, Borkham-Kamphorst E, Geisler C, Berger T, Mak TW, Knüchel R, Meyer HE, Weiskirchen R, Henkel C. Labbus K, et al. Among authors: weiskirchen r. J Proteomics. 2013 Jan 14;78:188-96. doi: 10.1016/j.jprot.2012.11.021. Epub 2012 Dec 3. J Proteomics. 2013. PMID: 23219901

10

The PDGF system and its antagonists in liver fibrosis.

Borkham-Kamphorst E, Weiskirchen R. Borkham-Kamphorst E, et al. Among authors: weiskirchen r. Cytokine Growth Factor Rev. 2016 Apr;28:53-61. doi: 10.1016/j.cytogfr.2015.10.002. Epub 2015 Oct 30. Cytokine Growth Factor Rev. 2016. PMID: 26547628 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results